行情

KIN

KIN

Kindred Bio
NASDAQ

实时行情|Nasdaq Last Sale

7.59
-0.11
-1.43%
盘后: 7.59 0 -0.02% 16:37 09/20 EDT
开盘
7.68
昨收
7.70
最高
7.79
最低
7.50
成交量
18.85万
成交额
--
52周最高
15.11
52周最低
5.96
市值
2.96亿
市盈率(TTM)
-4.6323
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KIN 新闻

  • 日美贸易协定冲击波:部分日本农民或“失业”
  • 中国经营报.5小时前
  • 法媒:沙特石油设施遭袭凸显石油行业脆弱性
  • 参考消息.8小时前
  • 亚马逊曾拟1500万美元收购奈飞 现在奈飞市值超千亿
  • 新浪美股.8小时前
  • 沙特称伊朗应为石油设施遇袭负责 伊方驳斥:毫无根据
  • 央视.9小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

KIN 简况

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
展开

Webull提供Kindred Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。